Harnessing the FOXO-SIRT1 axis: insights into cellular stress, metabolism, and aging
Biogerontology,
Journal Year:
2025,
Volume and Issue:
26(2)
Published: Feb. 26, 2025
Language: Английский
Targeting p70S6K1 Inhibits Glycated Albumin-Induced Triple-Negative Breast Cancer Cell Invasion and Overexpression of Galectin-3, a Potential Prognostic Marker in Diabetic Patients with Invasive Breast Cancer
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(3), P. 612 - 612
Published: March 3, 2025
Background:
There
is
an
urgent
need
to
identify
new
biomarkers
for
early
diagnosis
and
development
of
therapeutic
strategies
diabetes
mellitus
(DM)
patients
who
have
invasive
breast
cancer
(BC).
We
previously
reported
the
increased
activated
form
70
kDa
ribosomal
protein
S6
kinase
1
(phospho-p70S6K1)
in
a
triple-negative
BC
(TNBC)
cell
line
MDA-MB-231
exposed
glycated
albumin
(GA)
ductal
carcinoma
tissues
from
T2DM
patients,
compared
untreated
cells
their
non-diabetic
counterparts,
respectively.
Objective:
aimed
explore
function
p70S6K1
GA-promoted
TNBC
progression.
Methods:
By
employing
small
interference
(si)RNA
technology
or
blocking
its
activity
using
specific
pharmacological
inhibitor,
we
monitored
invasion
Transwell®
inserts
expression
levels
signaling
proteins
cancer-related
Western
blot.
Results:
In
silico
analysis
revealed
that
high
mRNA
were
associated
with
unfavorable
prognosis
progression
advanced
stages
DM
patients.
The
downregulation/blockade
inhibited
phosphorylation
ERK1/2,
downstream
effector,
key
oncogenic
protein,
suppression
GA-upregulated
proteins,
including
enolase-2,
capping
CapG,
galectin-3,
cathepsin
D,
was
observed
after
downregulation/blockade.
Further
validation
analyses
gene
galectin-3
resulting
poor
overall
survival
disease-free
survival.
Conclusions:
Targeting
may
present
valuable
strategy,
while
could
serve
as
potential
prognostic
biomarker
Language: Английский
Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology
Discover Nano,
Journal Year:
2025,
Volume and Issue:
20(1)
Published: April 24, 2025
Cancer
treatments
often
exploit
oxidative
stress
to
selectively
kill
tumour
cells
by
disrupting
their
lipid
peroxidation
membranes
and
inhibiting
antioxidant
enzymes.
However,
plays
a
dual
role
in
cancer
progression,
acting
as
both
promoter
suppressor.
Balancing
through
therapy
remains
challenge,
excessive
activity
may
compromise
the
efficacy
of
chemotherapy
radiotherapy.
This
review
explores
antioxidants
mitigating
while
maintaining
treatment
efficacy.
It
highlights
recent
advancements
nanotechnology-based
targeted
delivery
optimize
therapeutic
outcomes.
A
comprehensive
literature
was
conducted
using
reputable
databases,
including
PubMed,
Scopus,
Web
Science,
ScienceDirect.
The
search
focused
on
publications
from
past
five
years
(2020-2025),
supplemented
relevant
studies
earlier
years.
Keywords
such
"antioxidants,"
"lipid
peroxidation,"
"nanotechnology
therapy,"
"oxidative
stress"
were
utilized.
Relevant
articles
critically
analysed,
graphical
illustrations
created.
Emerging
evidence
suggests
that
nanoparticles,
liposomes,
polymeric
metal-organic
frameworks,
others,
can
effectively
encapsulate
control
release
minimizing
systemic
toxicity.
Stimuli-responsive
carriers
with
tumour-specific
targeting
mechanisms
further
enhance
delivery.
Studies
indicate
these
strategies
help
preserve
normal
cells,
mitigate
stress-related
damage,
improve
challenges
bioavailability,
stability,
potential
interactions
standard
therapies
remain.
Integrating
nanotechnology
antioxidant-based
interventions
presents
promising
approach
for
optimizing
therapy.
Future
research
should
focus
refining
modulation
strategies,
assessing
profiles
during
treatment,
employing
biomarkers
determine
optimal
dosing.
balanced
use
adverse
effects.
Language: Английский